Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
- Alzheimerâ€™s disease
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 179565
Licensed Intellectual Property Product/Precursor Ions diagnostic of a DHEA Precursor Detected in Human Serum as Potential Biomarkers for the Determination of Alzheimerâ€™s Disease. McGill ROI 15073.
IPSCIO Record ID: 310824
Pursuant to the agreement, the Licensor will receive royalty payments on the LymPro intellectual property in addition to being issued 49.9% of its ordinary shares in exchange for equity interest.
Licensor is a biotechnology company focused on developing diagnostics in neurology, and therapeutic products with the potential for orphan drug designation in the areas of neurology, psychiatry, ophthalmology and regenerative medicine to diagnose Alzheimerâ€™s disease.
Licensee aims to develop and bring to market its revolutionary blood tests for disease detection that includes Alzheimers disease.
IPSCIO Record ID: 27552
This Agreement initially contemplates a transfer of existing Alzheimer Therapeutic Know-how to Licensee. Pursuant to such initial transfer and continuing collaboration thereafter, it is contemplated that Licensee will determine the amino add sequence of proteins and base sequence of nucleic acids, generate monoclonal antibodies, done and express and assess biological and therapeutic activity of proteins, all related to the Field of this Agreement.
In addition, Licensee will engage in a collaborative research project directed to the Field and funded by Licensee, which collaboration is contemplated to include
a. development by Licensee of therapeutics based on specific materials provided; and
b. other related research and development related to the development by Licensee of therapeutics for Alzheimer's disease.
IPSCIO Record ID: 125020